Detail akcie Neurocrine Bios online

Business Summary: Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).
Financial Summary: BRIEF: For the three months ended 31 March 2024, Neurocrine Biosciences, Inc. revenues increased 23% to $515.3M. Net income totaled $43.4M vs. loss of $76.6M. Revenues reflect Collaboration revenue increase of 24% to $6.3M. Net Income reflects Acquired in-process research and develop decrease of 96% to $6M (expense), Investment income and other, net increase from $9.8M to $23.4M (income).